<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002826</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065011</org_study_id>
    <secondary_id>E-1195</secondary_id>
    <nct_id>NCT00002826</nct_id>
  </id_info>
  <brief_title>Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a&#xD;
      chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating&#xD;
      women who have recurrent or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the antitumor activity, as measured by frequency of objective&#xD;
      response and time to progression, of the multidrug resistance modulator PSC 833 in&#xD;
      combination with paclitaxel in women with recurrent or metastatic breast cancer. II. Describe&#xD;
      the toxicity of this regimen.&#xD;
&#xD;
      OUTLINE: All patients receive PSC 833 by mouth every 6 hours for a total of 12 doses.&#xD;
      Paclitaxel is infused over 3 hours, after the 5th dose of PSC 833. Treatment is repeated&#xD;
      every 3 weeks in stable and responding patients. PSC 833 must not be mixed with grapefruit&#xD;
      juice. Growth factors may be used at the discretion of the investigator. Patients are&#xD;
      followed every 3 months for the first two years, then every 6 months for years 2-5, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: It is anticipated that approximately 36 patients will be entered over 24&#xD;
      months if there are at least 6 responses in the first 17 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valspodar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the breast that is&#xD;
        recurrent or metastatic No CNS metastases Bidimensionally measurable disease required&#xD;
        Patients with bone sites only are not eligible Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Women only Menopausal status: Not specified&#xD;
        Performance status: ECOG 0-2 Hematopoietic: Platelet count at least 100,000/mm3 Absolute&#xD;
        granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST less&#xD;
        than 2.5 times upper limit of normal Renal: Creatinine no greater than twice upper limit of&#xD;
        normal Other: No allergy to cyclosporine or to drugs formulated with Cremophor (e.g., some&#xD;
        anesthetics and muscle relaxants) No active unresolved infection More than 7 days since&#xD;
        parenteral antibiotics No second malignancy within 5 years except: In situ cervical cancer&#xD;
        Nonmelanomatous skin cancer No pregnant or nursing women Adequate contraception required of&#xD;
        fertile women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior&#xD;
        anthracyclines or medical contraindication to anthracycline therapy required No prior&#xD;
        paclitaxel or taxotere No more than 1 prior regimen for metastatic or recurrent disease&#xD;
        Adjuvant chemotherapy within 6 months of diagnosis of metastatic disease considered therapy&#xD;
        for advanced disease At least 3 weeks since chemotherapy Endocrine therapy: At least 3&#xD;
        weeks since hormonal therapy for metastases Radiotherapy: Not specified Surgery: Not&#xD;
        specified Other: No concurrent treatment with any of the following agents proven to affect&#xD;
        blood levels of cyclosporine: Diltiazem Nicardipine Verapamil Fluconazole Itraconazole&#xD;
        Ketoconazole Clarithromycin Erythromycin Methylprednisolone Prednisolone Allopurinol&#xD;
        Bromocriptine Danazol Metoclopramide Nafcillin Rifampin Carbamazepine Phenobarbital&#xD;
        Phenytoin Octreotide Ticlopidine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W. Carlson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunterdon Regional Cancer Program</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimball Medical Center</name>
      <address>
        <city>Lakewood</city>
        <state>New Jersey</state>
        <zip>08701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Center</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Carlson RW, O'Neill A, Goldstein L, et al.: A phase II trial of PSC-833 modulation of multidrug resistance to paclitaxel in breast cancer: a pilot trial of the Eastern Cooperative Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-234, 2002.</citation>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2004</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

